In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Approvals And Up-Fronts: Our Methodology

Executive Summary

In the first part of a new series, we took the data used to produce our 2014 study and reviewed the actual outcomes of the deals in terms of the current development status of the partnered programs to see how they matched up against BioMedTracker's likelihood of approval (LOA) predictions.

We re-evaluated the partnerships – approximately 394 during 2003 to 2011 – from the original dataset in Informa's Strategic Transactions, including deals for Phase I to III candidates across seven therapeutic areas – cancer, cardiology, immune, infectious, metabolic, neurology, and respiratory. Deals included were restricted to those with a disclosed up-front value of at least $1 million.

Approximately 119 deals out of the 394 had been terminated but were included in the analysis. Of the 119, 22 deals produced an approved drug, post deal-termination.

The drugs that were included were the ones that were part of the original deal terms and associated with that up-front payment.

To determine the current phase of the drug, we used Informa's BioMedTracker, Medtrack, or PharmaProjects.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts